MINE in the treatment of relapsed or refractory non-Hodgkin#39;s lymphoma 23 cases of.docVIP

 PAGE \* MERGEFORMAT 14 MINE in the treatment of relapsed or refractory non-Hodgkin#39;s lymphoma 23 cases of 【Abstract】 Objective To observe the MINE (MIT, VP16, IFO) in the treatment of relapsed and refractory non-Hodgkin’s lymphoma efficacy and toxicity. Methods 23 patients with failure of CHOP in the treatment of NHL patients MINE regimen for at least two cycles, MIT 6 ~ 8mg/m2/d, infusion, d1; IFO 2.0 infusion, d1 ~ 3, with Mesna 400mg / times , 0h, 4h, 8h bolus 3 times; VP16 80mg/m2/d, intravenous infusion, d1 ~ 3. Determine the efficacy and toxicity according to WHO standards. The results of complete remission (CR) 5 patients and partial remission (PR) 10 cases of stable (SD) 3 cases of progress (PD) 5 cases, the total effective rate (CR PR) 65.2%, the main toxicity was myelosuppression, WBC to reduce the rate of 73.9%, to the main Ⅰ ~ Ⅱ degrees. The G  CSF support after return to normal, non-and toxicity-related death occurred. Conclusion MINE in the treatment of refractory NHL have a higher efficacy and more secure, the patient can be tolerated. Keywords: Non-Hodgkin’s lymphoma chemotherapy refractory Malignant non-Hodgkin’s lymphoma (Non  Hodgkin lymphoma, NHL) pathological classification more complicated, pathological type and degree of malignancy and the treatment plan and prognosis are closely linked. For the newly diagnosed NHL in general are used in a high degree of CHOP chemotherapy, complete remission rate of up to 51% ~ 54% [1]. CHOP regimen, but some patients still have ineffective or recent relapse, making it difficult to achieve the desired clinical effect. Have a variety of domestic and international relief programs for the relapse cases, the predominant drug ifosfamide (IFO), mitoxantrone (MIT), etoposide (VP16), cis-platinum (DDP), have reported that there were certain effect [2]. This article summarizes our department in January 2003 ~ June 2005 by MIT, IFO, VP16 formed MINE in the treatment of highly refrac